- Home
- EYPT
as 11-25-2025 3:39pm EST
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 967.4M | IPO Year: | 2005 |
| Target Price: | $29.60 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.91 - $14.91 | Next Earning Date: | 11-05-2025 |
| Revenue: | $42,339,000 | Revenue Growth: | -7.38% |
| Revenue Growth (this year): | -13.63% | Revenue Growth (next year): | -56.51% |
Stock Insider Trading Activity of EyePoint Pharmaceuticals Inc. (EYPT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ribeiro Ramiro | EYPT | Chief Medical Officer | Nov 11 '25 | Sell | $11.61 | 2,722 | $31,602.42 | 0 |
Latest EyePoint Pharmaceuticals Inc. News
EYPT Breaking Stock News: Dive into EYPT Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday
MT Newswires
6 days ago
EyePoint Gets Positive Recommendation for Wet AMD Trials From Safety Committee
GlobeNewswire
7 days ago
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
GlobeNewswire
9 days ago
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Simply Wall St.
a month ago
With 57% institutional ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) is a favorite amongst the big guns
GlobeNewswire
a month ago
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025
Barrons.com
2 months ago
Biotech Stocks Rally. 3 Favorite Plays From the Charts.
MT Newswires
5 months ago
RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target
Compare EYPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EYPT EyePoint Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.